This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Mexico aims to conduct late stage trials for coronavirus vaccines designed by US and Chinese companies. This is in hope that these countries may base their vaccine production in Mexico. Ebrard said he hoped that trials would start between next month and January if they get approval from Mexico’s food and drug agency.
She also once interned at Wenzhou Institute, University of Chinese Academy of Sciences and participated in the research of photocurable protein-based hydrogels for developing an in vitro liver model for hepatitis drug screening. Haiqi Chen Haiqi Chen is a graduate student from the Department of Biological Science at Columbia University.
This spring we’ve been quite fortunate to be joined by 6 Master’s students from Columbia University, who have been contributing to our creation of community resources as part of their Seminar in Biotechnology Course. Haiqi Chen Haiqi Chen is a graduate student from the Department of Biological Science at Columbia University.
Start Date End Date Event Event Type Organization 2/28/2024 2/28/2024 Workshop on Medical Radioisotopes Conference ( CLOSED ) Belgian Council Presidency 2/28/2024 2/28/2024 The path to diagnosis – the challenge of rare diseases Webinar/ Seminar ( OPEN ) Martin Zeitz Center for Rare Diseases at the University Hospital Hamburg-Eppendorf 2/28/2024 (..)
There will also be a number of noteworthy conferences taking place this month pertaining to the vaccine and medical technology industries. Many of these webinars and trainings sessions are geared towards medical devices and in vitro diagnostics (IVDs). s Medicines and Healthcare products Regulatory Agency (MHRA).
Upcoming Webinar Hosted by Xtalks Webinar/Seminar ( OPEN) Xtalks 11/6/2023 11/6/2023 What is the evidence for high-risk medical devices in the field of cardiovascular disease and diabetes?
FDA fiscal year in review: New drug approvals in the wake of the pandemic and legislative reforms AgencyIQ analyzed CDER’s novel drug approvals in Fiscal Year 2023, identifying a recovery in approval numbers as the agency resumes a new normal following the pandemic. As a reminder, the U.S.
Start Date End Date Event Event Type Organization 8/5/2024 8/8/2024 PRAC August meeting Committee Meeting ( CLOSED ) Pharmacovigilance Risk Assessment Committee (PRAC) 8/6/2024 8/6/2024 Infectious Diseases Working Party Seminar ( CLOSED ) British In Vitro Diagnostics Association (BIVDA) 08/12/2024 5 weeks Explore innovative personalized therapeutic (..)
Positive August 2024 Eurneffy (epinephrine) Ars Pharmaceuticals Irl Limited Positive August 2024 MResvia (Respiratory Syncytial Virus mRNA vaccine) Moderna Biotech Spain S.L. The information below includes the event type and whether the meeting can be attended by the public (Open) or not (Closed).
A January 2022 Seminars in Arthritis and Rheumatism publication noted that a “generic [drug] may only cost $1 million to $4 million and take two years to develop vs $100 million to $250 million and seven to eight years for a biosimilar.” Those studies lasted a median of 55 weeks (IQR: 46-78) and cost a median of $27.6
The European Commission also plans to create a Critical Medicines Alliance for a more coordinated effort in managing drug shortages within the E.U. We are expecting to see the release of an E.U. This effort will most likely be set up in early Q1 of 2024.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content